We are investigating the safety of INT2104 infusions for adults with B-cell cancers that have returned after previous treatments. This study aims to understand how well this new treatment works in this patient group.
Health conditions and diseases that the clinical trial is designed to study and treat.
Refractory B-Cell Malignancies are types of blood cancers that do not respond to standard treatments, including acute lymphoblastic leukemia and certain forms of B-cell non-Hodgkin lymphoma. These conditions can be challenging to treat and often require advanced therapies.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
